Key Highlights

  • Eli Lilly shares are trading up 3.28% to $1,195.51 in Wednesday's session, well ahead of the broader healthcare sector.
  • The FDA expanded approval for Jaypirca to include first-line treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma.
  • A brokerage raised its price target to $1,430 with an Overweight rating following the approval.
  • Second-quarter results showed Revenue up 48% year over year, with 2026 guidance extended to $85 billion to $87 billion.

Expanded Approval Drives a Sharp Move Higher

Eli Lilly (NYSE:LLY) shares are trading sharply higher in Wednesday's session after the FDA expanded approval for Jaypirca to cover first-line treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma, broadening the drug's addressable patient population. The news prompted a brokerage to raise its price target on the stock to $1,430 with a bullish outlook, adding further momentum to the day's gain.

Obesity Pipeline Continues to Anchor Investor Enthusiasm

Beyond the Jaypirca approval, sentiment has also been supported by continued enthusiasm for the company's amylin-based obesity candidate, eloralintide, which has drawn attention as a potential next-generation addition to its metabolic disease portfolio alongside existing therapies. Second-quarter results showed revenue growth of 48% year over year, prompting the company to extend its 2026 revenue guidance to a range of $85 billion to $87 billion.

Pricing pressure on the company's existing obesity Franchise and a premium valuation relative to peers remain the main points of debate among investors weighing the stock's current run-up.

Pipeline Breadth Keeps the Bullish Case Intact

With Jaypirca's expanded approval now in hand and the obesity pipeline still generating headlines, the stock's next test is likely to be whether upcoming data from the broader pipeline, spanning diabetes, immunology, and neuroscience, can sustain today's momentum. The company's scale and diversified revenue base continue to support its position as one of the sector's largest and most closely watched growth stories.